Ifosfamide encephalopathy and use of methylene blue. A case report of different sequential neurotoxicity

Petros Giovanis¹, Antonella Garna², Marilisa Marcante¹, Katiuscia Nardi¹, and Mauro Giusto¹

¹Operative Unit of Medical Oncology, ²Department of Pharmacy, City Hospital of Belluno, Belluno, Italy

ABSTRACT

Neurotoxicity is a clinically relevant adverse event observed with the use of ifosfamide. It is usually mild, occasionally severe and seldom fatal. Ifosfamide-induced encephalopathy requires interruption of chemotherapy, intravenous hydration and administration of methylene blue. Less is known about the efficacy of methylene blue in avoiding a second episode of ifosfamide-induced encephalopathy while maintaining chemotherapy with ifosfamide. We report a case of a different clinical manifestation of ifosfamide-induced encephalopathy after continued ifosfamide use and despite methylene blue in a patient with retroperitoneal sarcoma.

Key words: ifosfamide, methylene blue, neurotoxicity, sarcoma.

Correspondence to: Petros Giovanis, MD, Operative Unit of Medical Oncology, City Hospital of Belluno, Viale Europa 22, 32100 Belluno, Italy.
Tel +39-0437-516178, +39-0437-516515;
fax +39-0437-516522;
e-mail petros.giovanis@ulss.belluno.it

Received August 25, 2008; accepted September 17, 2008.